Navigation Links
Medisafe 1 Technologies Announces the Ex-Dividend Date on April 30 2013, Record Date on May 3 2013 and the Payment Date on May 6 2013
Date:1/28/2013

JERUSALEM, January 28, 2013 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company intends to issue the one-time special dividend to all existing shareholders pursuant to the perpetual license sale of technology rights to SAFECODE DRUG TECHNOLOGIES CORP.

The dates of the dividend are as follows:

Ex-Dividend date for its dividend to its Shareholders on April 30 2013, record date on May 3 2013 and the payment date on May 6 2013.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle.  Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:

Jacob Elhadad , CEO
+972-524440000
Jacob.elhadad10@gmail.com


'/>"/>
SOURCE Medisafe 1 Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medisafe 1 Technologies Signs the $7MM Perpetual License Agreement
2. Medisafe 1 Technologies Announces Delay in Closing $7MM Perpetual License Sale Due to Hurricane Sandy
3. Medisafe 1 Technologies Anticipates a Special Dividend of $0.01 (One Cent) to Each Shareholder of One Common Stock pending the $7MM Perpetual License Sale of Technology Rights
4. Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
5. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
6. Masimo Showcases Advanced, Noninvasive Patient Monitoring Technologies at Arab Health
7. FCS Express Compatible with Life Technologies Tali Image Based Cytometer
8. SafeCode Drug Technologies Corp Signs an Agreement With INTOVISION PRODUCT DEVELOPMENT & DESIGN (An Israeli Product Development Co) to Manufacturers the Worlds First Voice Recognition Drug Safety Application Prototype
9. UV Flu Technologies Outlines Distribution and Expansion Plans for 2013
10. Cumberland Emerging Technologies Expands Life Sciences Center
11. Blue Belt Technologies annonce que le Golden Jubilee National Hospital a réalisé la première opération NavioPFS darthroplastie unicondylaire du genou
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
(Date:7/11/2014)... MELBOURNE, Australia , July 11, 2014  Australian ... today announced that it has raised A$19.3 million via ... Europe , the U.S., ... and A$3 million from a share purchase plan (SPP) ... A$16.3 million will be made in two tranches. ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... A. Grant, MD,Retina Macular Care, presented the ... that was designed to evaluate the adjuvant,use ... Lucentis(R),(ranibizumab) treatment of choroidal neovascularization secondary to,age-related ... presentation at,the 2008 Annual Meeting of the ...
... C Therapies Provides ... Clinical Practice, MILAN, Italy, April 26 Final ... study comparing the,leading therapies for chronic hepatitis C, were ... Association for the Study of the Liver,(EASL), providing important ...
Cached Medicine Technology:Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
(Date:7/11/2014)... London, UK (PRWEB) July 11, 2014 ... segment of the in-vitro diagnostics industry, which is expected ... next ten years. The sector owes its growth to ... threat to people’s health worldwide and a major factor ... diagnostic technologies, threat of bio-terrorism, and a broader availability ...
(Date:7/11/2014)... Utilizing the Keller Funnel, Quatela Center for ... a record number of complication-free breast augmentations. Far ... procedures without the occurrence of a capsular contraction. ... country for his expertise with the breast augmentation procedure. ... foundation for numerous studies and research. Most recently, ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is ... Concord Pavilion . When it comes to the summer concert ... The 37-year-old Georgia native is one of the biggest names in ... business. Bryan is currently out on his “That’s My Kind of ... stops the tour will be making through the rest of the ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
(Date:7/11/2014)... kind has found that organic foods and crops ... counterparts, including more antioxidants and fewer, less frequent ... unprecedented 343 peer-reviewed publications comparing the nutritional quality ... including fruits, vegetables, and grains. The study team ... organic and non-organic foods. , "Science marches ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... Kathleen Doheny HealthDay Reporter , THURSDAY, Oct. 7 ... cancer who have dense breasts may be at higher risk ... breast, a new study indicates. "The risk appears to ... that originally had the cancer," said Laurel A. Habel, a ...
... (Oct. 7, 2010)In 2006, Dr. Shimya Yaminaka of Kyoto ... medicine research world on fire when he successfully transformed ... behave like embryonic stem cells. Embryonic stem cells, the ... the ability to differentiate into any type of tissue. ...
... which participants are randomly assigned to different treatments by ... correctly, it,s widely accepted by the research community that ... But researchers at the University of Michigan ... medical devices to patients by investigating the impact of ...
... HealthDay Reporter , WEDNESDAY, Oct. 6 (HealthDay News) ... be taken with the blood thinner Plavix, a new ... medications, called PPIs, might interfere with the ability of ... reassuring data that there is not any clinically significant ...
... perhaps more than anyone realizes -- in basic biological ... reducing cancer risks, according to University of Oregon researchers. ... zebrafish, scientists in the UO Institute of Molecular Biology ... in the sterile environment of its eggshell through the ...
... friends and family members of mood history and symptoms ... research published online by the journal International Psychogeriatrics ... who is highly outgoing and fun-loving and who is ... miss the signs that indicate the person is depressed. ...
Cached Medicine News:Health News:Denser Breasts Raise Odds of Second Breast Cancer, Study Finds 2Health News:Denser Breasts Raise Odds of Second Breast Cancer, Study Finds 3Health News:Colorado researcher discovers mechanism for changing adult cells into stem-like cells 2Health News:U-M receives NIH, FDA grant to study adaptive clinical trial designs 2Health News:Heartburn Drugs, Plavix Seem Safe to Take Together 2Health News:Heartburn Drugs, Plavix Seem Safe to Take Together 3Health News:Gut microbes promote cell turnover by a well-known pathway 2Health News:Patient personality hinders detection of depression 2